By Dean Seal
Nuvation Bio said federal regulators have cleared an investigational new drug application for its treatment of advanced solid tumors, NUV-1511.
The biopharmaceutical company said Monday that the Food and Drug Administration's clearance makes NUV-1511 the first clinical candidate from the company's novel drug-drug conjugate platform.
"This IND clearance expands our clinical pipeline and validates the approach of our proprietary DDC platform to design potent oncology-focused chimeric small molecules which combine tumor-targeting specificity with the anti-cancer activity of known oncology agents," Chief Executive David Hung said.
The company said it expects to launch a Phase 1/2 study of NUV-1511 in the first half of this year.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
01-08-24 1643ET